Figure 5
From: Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
cHcAb6 binds to native CTLA4 on cPBMCs. CPBMCs were stimulated with PMA and Ionomycin for 8 h. Activated and control PBMCs were stained with cHcAb6 and analyzed by flow cytometry using anti-canine IgG Fc-750 Ab. Canine IgG was used as an isotype control. The CTLA4 expression was markedly increased after PMA/Ionomycin stimulation.
